Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

OBJECTIVE: To evaluate the safety and efficacy of cladribine tablets in patients still experiencing active relapsing MS despite interferon (IFN)-β treatment. METHODS: A 96-week phase II study, randomizing patients treated with IFN-β to cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β. Patients we...

Descripción completa

Detalles Bibliográficos
Autores principales: Montalban, Xavier, Leist, Thomas P., Cohen, Bruce A., Moses, Harold, Campbell, Jackie, Hicking, Christine, Dangond, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047834/
https://www.ncbi.nlm.nih.gov/pubmed/30027104
http://dx.doi.org/10.1212/NXI.0000000000000477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047834/
https://www.ncbi.nlm.nih.gov/pubmed/30027104
http://dx.doi.org/10.1212/NXI.0000000000000477

Ejemplares similares